Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Other Non-Current Liabilities (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Other Non-Current Liabilities for 8 consecutive years, with $1.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Liabilities fell 81.67% year-over-year to $1.1 million, compared with a TTM value of $1.1 million through Sep 2025, down 81.67%, and an annual FY2024 reading of $1.1 million, down 75.52% over the prior year.
  • Other Non-Current Liabilities was $1.1 million for Q3 2025 at Bicycle Therapeutics, down from $1.1 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $6.0 million in Q3 2024 and bottomed at $1.1 million in Q3 2025.
  • Average Other Non-Current Liabilities over 5 years is $3.3 million, with a median of $3.3 million recorded in 2021.
  • The sharpest move saw Other Non-Current Liabilities skyrocketed 42.01% in 2021, then crashed 81.67% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $3.3 million in 2021, then rose by 16.77% to $3.8 million in 2022, then rose by 19.59% to $4.6 million in 2023, then tumbled by 75.52% to $1.1 million in 2024, then dropped by 2.5% to $1.1 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for BCYC at $1.1 million in Q3 2025, $1.1 million in Q2 2025, and $1.1 million in Q1 2025.